Cadrenal Therape Financials
This page shows Cadrenal Therape (CVKD) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Cadrenal’s finances currently behave like a cash-runway business, with operating burn—not asset investment—driving nearly all balance-sheet change.
From FY2023 to FY2025, operating cash burn rose from$3.5M to$12.6M . At the same time, year-end cash fell from$8.4M to$4.0M , and free cash flow stayed nearly identical to operating cash flow for three straight years, showing the drain came from running the organization itself rather than building long-lived assets.
The expense mix changed materially: SG&A grew from
FY2025 still showed a current ratio of 2.7x, so near-term bills were covered on paper. But that cushion sat on only
Financial Health Signals
We are recalculating Cadrenal Therape's peer-relative financial health score against the latest fiscal year. It will appear here once the refresh completes. The signals and metrics below are current.
Cadrenal Therape passes 1 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
Cadrenal Therape reported a net loss of $13.2M while operations used $12.6M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Cadrenal Therape's EBITDA was -$13.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 22.8% from the prior year.
Cadrenal Therape reported -$13.2M in net income in fiscal year 2025. This represents a decrease of 24.3% from the prior year.
Not reported for fiscal year 2025.
Cash & Balance Sheet
Cadrenal Therape recorded an outflow of $12.6M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents a decrease of 71.2% from the prior year.
Cadrenal Therape held $4.0M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Cadrenal Therape paid $16.50 per share in dividends in fiscal year 2025.
Margins & Returns
Cadrenal Therape's ROE was -483.3% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 340.2 percentage points from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Capital Allocation
Cadrenal Therape invested $4.1M in research and development in fiscal year 2025. This represents a decrease of 2.5% from the prior year.
Cadrenal Therape invested $5K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 21.9% from the prior year.
Not reported for fiscal year 2025.
CVKD Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY08 |
|---|---|---|---|---|---|---|
| Cost of Revenue | N/A | N/A | N/A | $220K | N/A | $220K |
| R&D Expenses | N/A | $4.1M-2.5% | $4.2M+3.0% | $4.1M+938.9% | $393K | $200K |
| SG&A Expenses | N/A | $9.4M+38.5% | $6.8M+90.3% | $3.5M+53.8% | $2.3M | N/A |
| Operating Income | N/A | -$13.5M-22.8% | -$11.0M-43.6% | -$7.6M-182.5% | -$2.7M | N/A |
| Interest Expense | N/A | N/A | N/A | $4K-91.2% | $40K | N/A |
| Net Income | N/A | -$13.2M-24.3% | -$10.7M-27.5% | -$8.4M | N/A | N/A |
| EPS (Diluted) | — | -$6.64 | -$8.73 | -$9.29 | -$0.85 | N/A |
Not reported in any period shown, so not listed: Revenue, Gross Profit, Income Tax.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
No annual filing on record for: FY2009, FY2010, FY2011, FY2012, FY2013, FY2014, FY2015, FY2016, FY2017, FY2018, FY2019, FY2020, FY2021.
CVKD Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY08 |
|---|---|---|---|---|---|
| Total Assets | $4.3M-57.3% | $10.1M+18.8% | $8.5M+994.8% | $778K | N/A |
| Current Assets | $4.3M-57.3% | $10.1M+19.1% | $8.5M+1067.2% | $728K | N/A |
| Cash & Equivalents | $4.0M-60.0% | $10.0M+19.2% | $8.4M+25685.6% | $33K | N/A |
| Total Liabilities | $1.6M-40.8% | $2.7M+224.6% | $827K-86.9% | $6.3M | N/A |
| Current Liabilities | $1.6M-40.8% | $2.7M+224.6% | $827K-38.0% | $1.3M | N/A |
| Total Equity | $2.7M-63.2% | $7.4M-3.3% | $7.7M+238.6% | -$5.6M | N/A |
| Retained Earnings | -$39.0M-51.5% | -$25.7M-70.7% | -$15.1M-124.5% | -$6.7M | N/A |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
No annual filing on record for: FY2009, FY2010, FY2011, FY2012, FY2013, FY2014, FY2015, FY2016, FY2017, FY2018, FY2019, FY2020, FY2021.
CVKD Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY08 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -$10.2M | -$12.6M-71.3% | -$7.4M-108.4% | -$3.5M-193.0% | -$1.2M | N/A |
| Capital Expenditures | N/A | $5K-21.9% | $7K+100.9% | $3K+42.8% | $2K | N/A |
| Free Cash Flow | N/A | -$12.6M-71.2% | -$7.4M-108.4% | -$3.5M-192.7% | -$1.2M | N/A |
| Investing Cash Flow | N/A | -$5K+21.9% | -$7K-100.9% | -$3K-42.8% | -$2K | N/A |
| Financing Cash Flow | $7.0M | $6.6M-26.5% | $9.0M-24.6% | $11.9M+860.2% | $1.2M | N/A |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
No annual filing on record for: FY2009, FY2010, FY2011, FY2012, FY2013, FY2014, FY2015, FY2016, FY2017, FY2018, FY2019, FY2020, FY2021.
CVKD Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY08 |
|---|---|---|---|---|---|
| Return on Equity | -483.3%-340.2pp | -143.2%-34.5pp | -108.6% | N/A | N/A |
| Return on Assets | -305.9%-200.7pp | -105.2%-7.1pp | -98.1% | N/A | N/A |
| Current Ratio | 2.72-1.0x | 3.77-6.5x | 10.27+9.7x | 0.55 | N/A |
| Debt-to-Equity | 0.58+0.2x | 0.36+0.3x | 0.11 | N/A | N/A |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, FCF Margin.
No annual filing on record for: FY2009, FY2010, FY2011, FY2012, FY2013, FY2014, FY2015, FY2016, FY2017, FY2018, FY2019, FY2020, FY2021.
Similar Companies
Where Cadrenal Therape Ranks
Frequently Asked Questions
Is Cadrenal Therape profitable?
No, Cadrenal Therape (CVKD) reported a net income of -$13.2M in fiscal year 2025.
What is Cadrenal Therape's EBITDA?
Cadrenal Therape (CVKD) had EBITDA of -$13.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
Does Cadrenal Therape pay dividends?
Yes, Cadrenal Therape (CVKD) paid $16.50 per share in dividends during fiscal year 2025.
What is Cadrenal Therape's return on equity (ROE)?
Cadrenal Therape (CVKD) has a return on equity of -483.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Cadrenal Therape's free cash flow?
Cadrenal Therape (CVKD) recorded an outflow of $12.6M in free cash flow during fiscal year 2025. This represents a -71.2% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Cadrenal Therape's operating cash flow?
Cadrenal Therape (CVKD) recorded an outflow of $12.6M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Cadrenal Therape's total assets?
Cadrenal Therape (CVKD) had $4.3M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Cadrenal Therape's capital expenditures?
Cadrenal Therape (CVKD) invested $5K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Cadrenal Therape spend on research and development?
Cadrenal Therape (CVKD) invested $4.1M in research and development during fiscal year 2025.
What is Cadrenal Therape's current ratio?
Cadrenal Therape (CVKD) had a current ratio of 2.72 as of fiscal year 2025, which is generally considered healthy.
What is Cadrenal Therape's debt-to-equity ratio?
Cadrenal Therape (CVKD) had a debt-to-equity ratio of 0.58 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Cadrenal Therape's return on assets (ROA)?
Cadrenal Therape (CVKD) had a return on assets of -305.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Cadrenal Therape's cash runway?
Based on fiscal year 2025 data, Cadrenal Therape (CVKD) had $4.0M in cash against an annual operating cash burn of $12.6M. This gives an estimated cash runway of approximately 4 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Cadrenal Therape's Piotroski F-Score?
Cadrenal Therape (CVKD) has a Piotroski F-Score of 1 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Cadrenal Therape's earnings high quality?
Cadrenal Therape (CVKD) reported a net loss of $13.2M while operations used $12.6M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.